La cadena de opciones muestra datos clave de las opciones de acciones de Doximity a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Doximity..

Doximity (NYSE:DOCS) Bolsa, Cadena de Opciones

Doximity

Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AMCX

DOCS

SATS

TTWO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: SATS, TTWO, AXL, DOCS y AMCX.

5 acciones en el foco este viernes: SATS, TTWO, AXL, DOCS y AMCX

Doximity Inc

Canaccord Genuity analyst Maria Ripps maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Buy and lowers the price target from $76 to $72.

Price Target

Analyst Ratings

ETSY

Canaccord Genuity Maintains Buy on Etsy, Lowers Price Target to $72

While the second administration of President Donald Trump has created ripples across multiple sectors and factions, few entities are arguably as anxious about his leadership than China and businesses tied to the world's second-largest economy. With sharp rhetoric intersecting with stiff tariffs, the president has pulled no punches in his dealings with Beijing. Still, for the bold contrarian, opportunity may beckon.
Granted, the bullish narrative on China — especially its previously skyrocketing internet technology industry — presents significant risks. At the same time, it would be erroneous to assume that the case for Chinese stocks rests exclusively in the bearish domain. On the contrary, high-level arguments lend some credibility for optimism.
First, Beijing last year launched an initiative to tackle its struggling economy head-on through the aid of<a href="https://www.benzinga.com/markets/asia/25/01/43168134/is-chinas-economic-stimulus-strategy-helping-its-ailing-markets-to-recover"> stimulus packages targeting growth</a>. In December, Chinese leader Xi Jinping announced in a keynote speech that the economy was both stable and generating forward progress. In addition, he remarked that economic social and development objectives were on an encouraging trajectory.
It's not just empty words. Early indicators suggest that the government's efforts to boost the Chinese economy are<a href="https://www.benzinga.com/news/earnings/25/04/44608895/this-nasdaq-traded-lender-benefits-from-chinas-stimulus-measures"> breathing new life</a> into certain sectors. Further, Beijing's stimulus policies appear to have reinvigorated consumer credit demand. In turn, the enhanced activity could filter across the broader business ecosystem.
Another factor to consider is that the Trump 2.0 tariffs could force the Chinese to roll up its sleeves. This dynamic may inadvertently yield a competitive edge in terms of the nation's tech innovation. A worrying dilemma for Washington is Beijing's<a href="https://www.benzinga.com/tech/25/04/44892275/eric-schmidt-warns-china-is-going-to-win-ai-race-unless-washington-fights-with-funding-and-instills-american-values-at-the-core"> full-scale approach to artificial intelligence</a>. With the Chinese accelerating their AI spending, their prowess in the field could legitimately surpass that of the U.S.
Finally, there's evidence that President Trump himself may not be so willing to push his economic vision to the extreme. For example, following the White House's Liberation Day tariffs, the<a href="https://www.benzinga.com/personal-finance/25/04/44696616/dow-plunges-1178-points-after-trumps-liberation-day-tariffs-jd-vance-says-we-wont-fix-things-overnight"> market melted down</a>. More recently, Trump<a href="https://www.benzinga.com/markets/25/04/44942449/trump-pledges-substantial-cut-in-china-tariffs-but-refuses-to-make-it-zero-if-they-dont-make-a-deal-we-will-set-the-deal"> pledged a substantial cut in the high tariffs</a> placed on Chinese goods. Such an immediate concession speaks to the complex nature — and consequences — of major international levies.
The Direxion ETF: Those interested in taking a swing at the contrarian China narrative may consider financial service provider Direxion's China-focused exchange-traded fund. Specifically, the Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) seeks the daily investment results of 200% of the performance of the CSI Overseas China Internet Index.
Mainly, the CWEB ETF provides a convenient medium for leveraged speculation. Typically, those interested in leveraged trades must engage the options market, which can introduce its own risks and complexities. With CWEB, the individual shares (called units) can be transacted like any other publicly traded security. Therefore, the process is quick and intuitive.
Nevertheless, prospective participants should be aware of the high risks involved with leveraged ETFs. First, because of the leverage itself, the gains can be amplified but so can the losses. A few bad trades can easily overcome prior gains. Second, the CWEB is designed for exposure lasting for no longer than one day. Any longer than that and holders risk incurring value decay due to the daily compounding effect.
The CWEB ETF: While circumstances have been shaky, particularly in early April during the announcement of the Liberation Day tariffs, the CWEB ETF appears to be making a recovery effort.
<ul>
<li>Over the past year-and-a-half period, weekly demand trends have been largely negative, with more down weeks than up weeks being registered. In the last 10 weeks, the split was 50/50: five up weeks, five down.</li>
<li>Statistically, such "5-5" sequences with a negative tilt in the period feature a slightly upward bias or probability. Notably, in the past five sessions, CWEB has gained over 11%, indicating a possible rotation into Chinese equities.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1028" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28075144/image-193.png" alt="" class="wp-image-890699" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28075144/image-193.png 1028w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28075144/image-193-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28075144/image-193-1024x620.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28075144/image-193-768x465.png 768w" sizes="(max-width: 1028px) 100vw, 1028px" /></figure>
Featured image by <a href="https://pixabay.com/users/jeremy888-8000982/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7671354">Jeremy Zhu</a> from <a href="https://pixabay.com/photos/beijing-city-china-tall-building-7671354/">Pixabay</a>.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Long Ideas

Short Ideas

Technicals

ETFs

CWEB

Direxion's China-Focused CWEB ETF Offers Leveraged Speculation For Bold Contrarians

Plug expects net cash usage for Q1 2025 to be approximately $142 million compared to $268 million in Q1 2024.&nbsp;&nbsp; Net cash usage represents the change in unrestricted cash and cash equivalents, less proceeds from public and private offerings, net of transaction costs, and excludes principal payments of convertible instruments. Plug anticipates additional near-term reductions to net cash usage driven by hydrogen plant ramp-ups, additional cost downs, and additional price increases. The net cash usage for the first quarter 2025 could have been lower given the Company has been working with a key customer on a major price change and program enhancement which is effective from January 1, 2025 onwards

PLUG

Plug Power Signs $525M Yorkville Credit Facility, Prelim Q1 Revenue Seen At $130M–$134M (Vs. $131.01M Est.), Net Cash Usage at ~$142M

Canaccord Genuity analyst Michael Graham maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Buy and lowers the price target from $190 to $180.

ABNB

Canaccord Genuity Maintains Buy on Airbnb, Lowers Price Target to $180

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) with a Buy and maintains $23 price target.

Reiteration

TARA

HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

Venu Holding Corporation ("VENU" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VENU#NYSE">VENU</a>), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, announces a major milestone for its Sunset Amphitheater at El Paso development. The El Paso City Council has approved key amendments to its unique public-private partnership with VENU, advancing the vision for a world-class, multi-seasonal 12,500-seat outdoor music venue in the heart of the Cohen Entertainment District.

VENU

VENU Advances Sunset Amphitheater Development Following El Paso City Council Approval Of Key Public-Private Partnership Amendments

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $163 to $158.

NBIX

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $158

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h2 class="wp-block-heading">Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>)</h2>
<ul>
<li>Dividend Yield: 5.04%</li>
<li>JP Morgan analyst Jeremy Tonet downgraded the stock from Neutral to Underweight and cut the price target from $59 to $52 on April 8, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Scotiabank analyst Andrew Weisel maintained a Sector Perform rating and raised the price target from $58 to $61 on Dec. 12, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On April 23, Dominion Energy announced changes in senior executive responsibilities related to retirement of Diane Leopold.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest D <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="897" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074455/image-190.png" alt="" class="wp-image-890681" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074455/image-190.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074455/image-190-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074455/image-190-768x725.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</h3>
<ul>
<li>Dividend Yield: 5.08%</li>
<li>Barclays analyst Nicholas Campanella maintained an Equal-Weight rating and raised the price target from $47 to $48 on April 22, 2025. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Richard Sunderland downgraded the stock from Overweight to Neutral and cut the price from $50 to $44 on April 10, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 25, Portland Gen Electric posted downbeat quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest POR <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="898" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074531/image-191.png" alt="" class="wp-image-890682" style="width:527px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074531/image-191.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074531/image-191-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074531/image-191-768x729.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<h3 class="wp-block-heading">Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>)</h3>
<ul>
<li>Dividend Yield: 4.77%</li>
<li>Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating and cut the price target from $40 to $39 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Mizuho analyst Anthony Crowdell upgraded the stock from Underperform to Neutral and raised the price target from $32 to $36 on May 3, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: Avista will hold its quarterly conference call to discuss first quarter results on Wednesday, May 7.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">AVA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="897" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074605/image-192.png" alt="" class="wp-image-890683" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074605/image-192.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074605/image-192-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28074605/image-192-768x716.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Wall Street's Most Accurate Analysts Give Their Take On 3 Utilities Stocks Delivering High-Dividend Yields

WIIM

SPRB

Spruce Biosciences shares are trading lower after the company announced it approved a plan to implement a workforce reduction.

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Buy and maintains $75 price target.

CGON

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

SMX (Security Matters) PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXWW#NASDAQ">SMXWW</a>), a leader in providing "physical to digital" solutions for a circular economy, today unveiled a strategic alliance with Skypac Packaging, a Singapore-based producer of flexible plastic materials. Guided by the principle "Paper When Possible, Plastic When Useful," Skypac focuses on manufacturing PP, OPP, HDPE, and LDPE products-both with and without rotogravure printing-and aims to advance global packaging practices through this new collaboration with SMX.
By integrating SMX's invisible molecular marking and blockchain-based digital platform, Skypac seeks to bolster the sustainability and traceability of its plastic packaging line. SMX believes that with ongoing growth in cross-border trade and consumer demand for more eco-conscious products, the ability to verify a package's origins, composition, and end-of-life potential has become a competitive advantage. Skypac's offerings already serve multiple industries by preserving product freshness, minimizing shipping and storage costs, and providing an ideal canvas for branding. When combined with SMX's proprietary technology, these same packaging solutions can now be monitored across their entire lifecycle, enabling companies to reuse, recover, or turn them into an energy source at the end-of-life stage.

SMXWW

SMX Teams Up With Skypac to Boost Sustainability and Traceability in Global Plastic Packaging

PRTG

Portage Biotech shares are trading higher after the company reported confirmatory preclinical efficacy data for PORT-7.

Barrington Research analyst Vincent Colicchio maintains Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) with a Outperform and maintains $17 price target.

ASUR

Barrington Research Maintains Outperform on Asure Software, Maintains $17 Price Target

Biotech

Health Care

General

VRTX

The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion For Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Aged 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene.

Keybanc analyst Todd Thomas initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Overweight rating and announces Price Target of $38.

Initiation

Keybanc Initiates Coverage On Smartstop Self Storage with Overweight Rating, Announces Price Target of $38

Rosenblatt analyst Barton Crockett maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and maintains $36 price target.

CMCSA

Rosenblatt Maintains Neutral on Comcast, Maintains $36 Price Target

TD Securities analyst Andrew Charles maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and lowers the price target from $40 to $31.

JACK

TD Securities Maintains Hold on Jack In The Box, Lowers Price Target to $31

British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))))("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT&#x2122;, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract.

BCTX

BriaCell Showcases Phase 2 Results for Breast Cancer Therapy at Major Cancer Conference

CORRECTION: V2X Ticker Is 'VVX'

Ascendiant Capital analyst Edward Woo maintains Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) with a Buy and raises the price target from $7.5 to $9.

DUOT

Ascendiant Capital Maintains Buy on Duos Technologies Group, Raises Price Target to $9

Press Releases

Doximity to Present at the Jefferies London Healthcare Conference

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care

Legal

DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025

Doximity Announces Fiscal 2025 Third Quarter Financial Results

Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year

Doximity to Participate in the Raymond James 46th Annual Institutional Investors Conference

DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS

Comments

Doximity

Doximity (DOCS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL